Portable microfluidic raman system for rapid, label-free early disease signature detection

Technical Report · Tue Sep 01 00:00:00 EDT 2015

DOI:https://doi.org/10.2172/1222536· OSTI ID:1222536

Wu, Meiye ^[1]; Davis, Ryan Wesley ^[1]; Hatch, Anson ^[1]

---

1. Sandia National Laboratories (SNL-CA), Livermore, CA (United States)

In the early stages of infection, patients develop non-specific or no symptoms at all. While waiting for identification of the infectious agent, precious window of opportunity for early intervention is lost. The standard diagnostics require affinity reagents and sufficient pathogen titers to reach the limit of detection. In the event of a disease outbreak, triaging the at-risk population rapidly and reliably for quarantine and countermeasure is more important than the identification of the pathogen by name. To expand Sandia's portfolio of Biological threat management capabilities, we will utilize Raman spectrometry to analyze immune subsets in whole blood to rapidly distinguish infected from non-infected, and bacterial from viral infection, for the purpose of triage during an emergency outbreak. The goal of this one year LDRD is to determine whether Raman spectroscopy can provide label-free detection of early disease signatures, and define a miniaturized Raman detection system meeting requirements for low- resource settings.

• Research Organization: Sandia National Laboratories (SNL-CA), Livermore, CA (United States)
• Sponsoring Organization: USDOE National Nuclear Security Administration (NNSA)
• DOE Contract Number: AC04-94AL85000
• OSTI ID: 1222536
• Report Number(s): SAND--2015-8318; 606331
• Country of Publication: United States
• Language: English